Platinum-based chemotherapy plus cetuximab in head and neck cancer. - Wikidata - wikimedia - TriplyDB

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

http://www.wikidata.org/entity/Q33381094

about

HPV & head and neck cancer: a descriptive update Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab Patient-derived tumour xenografts as models for oncology drug development New advances in targeted gastric cancer treatment The promise of immunotherapy in head and neck squamous cell carcinoma Immunotherapy for head and neck cancer: latest developments and clinical potential The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential The Tip of the Iceberg: Clinical Implications of Genomic Sequencing Projects in Head and Neck Cancer Head and neck cancer: metronomic chemotherapy Advancements in the Management of HPV-Associated Head and Neck Squamous Cell Carcinoma Human Papillomavirus (HPV)-associated Oral Cancers and Treatment Strategies The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck Improving the efficacy of chemoradiation with targeted agents The role of microRNA in head and neck cancer: current knowledge and perspectives Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer The role of systemic treatment before, during, and after definitive treatment Radiotherapy and "new" drugs-new side effects?Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma Nanotechnology-based drug delivery systems for treatment of oral cancer: a review Clinical application of genetics to guide prevention and treatment of oral diseases Targeted therapy in advanced bladder cancer: what have we learned?Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity Epidermal growth factor receptor inhibitors: coming of age Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.

P2860

Q21198763-6A26C76F-8DC2-44F8-BF7F-3249A61ED602 Q21198850-2EEA03BC-12F2-4CF5-888E-3EC617CCF875 Q24200362-BE029285-9F5A-42B9-B46D-8FD745BD72FB Q24336818-A7283224-A35F-4EC8-AA98-1E580AB4E3B1 Q24600031-EBC2AC68-3108-46CD-A826-41399A6AE70D Q24604068-A63724F5-B0C2-4FE1-8446-91AA24F9024C Q26738548-0BCF4247-D730-4038-9CD1-68D048E07CDF Q26744433-B7D60058-E5AA-4AFD-BE54-B92E510FFEA7 Q26745428-BE7B337F-34D1-4F28-9E6D-52D2DF29F1CB Q26747516-BB0FF231-DBF5-4822-AD24-7AC25C8F82BE Q26750719-DF01D797-1BF9-4D5C-BE0E-3A2B407E4709 Q26752584-E51B7709-2F7B-49CC-AEF6-828BD7BEF32D Q26765060-D1C1DAD7-ECCA-4EC1-9B09-DD4EBBB41666 Q26765429-1E2571E8-8AB7-473C-8E9D-B88BE0B9F2A6 Q26767046-0E0DBD19-6D8F-4A2D-877D-CBADFF26EAEC Q26769610-87B72F5E-1D4D-4044-9F37-E4AB35DF1D12 Q26769884-DA82BCC6-2755-48EC-82D4-0D8C735AD118 Q26778433-9095C666-05AC-43C0-A74F-9E797943208A Q26784018-962C9FAC-E18D-441B-9961-72BCD3FADDBA Q26799543-B96CE80B-DA4A-4FEC-B638-19DA112B235A Q26822621-2367B3BB-4B32-4725-8C84-075542484329 Q26830495-563EF61B-5510-4BA0-8555-9F73FB3A1B45 Q26850193-24BB8800-56D4-457A-8470-B52B30B91C1B Q26851256-A9FA7F53-5C00-42FC-A80A-023CB0D0B930 Q26852215-74A2B0E8-9AD7-4FF3-A42A-F24A7D6FED22 Q26859285-C070F88F-63C0-47D3-A4BC-3AD33B14E68F Q26861498-1E89EA90-D909-4C67-AB9B-AA85CB33FE8F Q26862516-F7E48AE4-4233-43EB-B866-5D84D08C9F0F Q26991953-67C1F742-16FE-4D87-97AA-046DC5D01B8D Q26995835-2D82DC1C-2FE3-4591-B91A-01593B4CD27D Q26999507-4FCE494A-9FBA-4233-A930-6AEBED2888A2 Q27009469-216D8DE4-C9A7-48EF-9214-DD15830E2753 Q27009908-7262D202-AE91-4F3C-930B-D1B36DC0A713 Q27030769-AEA37A2E-74F9-46AC-9132-75180F0549A7 Q27851592-F9908147-AF2D-4CF0-8412-9ABCC26C38C8 Q27852901-EB49200D-CCE0-4E13-A650-4AD6F8CFCB63 Q27852908-34089822-AA6C-41E4-A1DF-D3074D63C19D Q27853003-CC2D3843-85B2-4BF1-BF8A-D1C6B1AA1D87 Q27853046-985F973C-B588-4592-96E7-67EE8C24AED5 Q27853173-F2A90833-D388-4CAC-A460-A2609245967F

P2860

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

http://www.wikidata.org/entity/Q33381094

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

@ast

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

@en

type

label

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

@ast

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

@en

prefLabel

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

@ast

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

@en

P1433

Q33381094-E4028C38-A3B6-4166-B92C-71EBF2C688BF

P1476

Q33381094-368F73FB-2C85-4A6C-B340-0D01330C3D0F

P2093

Q33381094-1D7644B3-3A7F-4E7D-9312-9BF73EBF73EC

Q33381094-1F7DCC62-D88D-4B6C-BD6D-F7762F108C03

Q33381094-5A6482D9-509F-47DD-9D38-DBA2B643C2BF

Q33381094-79A902D6-A1DB-4EBC-9A23-903802106DE4

Q33381094-859CDE2D-4BC2-4237-9656-88AA4BF3E098

Q33381094-8CFF66B1-FC5A-4F56-A41C-16DC4E1F98C6

Q33381094-94BC6352-D3E6-4D73-8939-94661467BD6F

Q33381094-9E5C5989-ED26-4B41-843E-02F8D8088F32

Q33381094-A4016768-2C1D-49E4-A7E0-BD8DF8484255

Q33381094-B200248F-B2AC-4601-87CC-A211A52A2F36

P304

Q33381094-423F47AB-6E5D-40EC-89C6-AEDB0BF8DA48

P31

Q33381094-EEDD56D6-5EF9-4F7F-8398-43DA425A873A

P356

Q33381094-535FB2CA-45DC-4490-A6E6-A058CC152B1F

P407

Q33381094-69D4A3E0-7D45-42FE-8052-E22E4DEDD6C9

P433

Q33381094-16FD42EA-8D65-42E3-BE2A-5A9BEA4F34B2

P478

Q33381094-2E26B5CA-F61B-4016-9E8A-F8FF62378576

P50

Q33381094-3F749317-04FF-4A62-AE7D-14454C275024

P577

Q33381094-15EF91FD-57BC-4C82-B36F-533F8DE65CBB

P5875

Q33381094-61D9C8E9-6324-4C33-855D-E8D5AC011325

P698

Q33381094-ADA6D2DA-85A8-4C8B-995D-6D66D9CB09A8

P921

Q33381094-A4BDE607-8C47-492D-BD0E-A56CFC7A1C8C

Q33381094-D0386E97-CC33-4A1F-86B6-C6488D222298

P356

P1433

The New England Journal of Medicine

P1476

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

@en

P2093

Andrzej Kawecki

http://www.w3.org/2001/XMLSchema#string

Armin Schueler

http://www.w3.org/2001/XMLSchema#string

Carsten Bokemeyer

http://www.w3.org/2001/XMLSchema#string

Didier Cupissol

http://www.w3.org/2001/XMLSchema#string

Dmytro Zabolotnyy

http://www.w3.org/2001/XMLSchema#string

Dominique De Raucourt

http://www.w3.org/2001/XMLSchema#string

Eva Remenar

http://www.w3.org/2001/XMLSchema#string

Fernando Rivera

http://www.w3.org/2001/XMLSchema#string

Frederic Peyrade

http://www.w3.org/2001/XMLSchema#string

Heinz-Roland Kienzer

http://www.w3.org/2001/XMLSchema#string

P304

1116-1127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0802656

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

Ihor Vynnychenko

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23249761

http://www.w3.org/2001/XMLSchema#string

P698

18784101

http://www.w3.org/2001/XMLSchema#string

P921